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ABSTRACT
Introduction: The efficacy and safety of
vedolizumab, a gut-selective a4b7 integrin
antibody, were demonstrated in the GEMINI 1
and GEMINI 2 clinical trials of adults aged
18–80 years. We investigated the efficacy and
safety of vedolizumab in patients stratified by
age from the GEMINI trials.
Methods: Safety and efficacy, including clinical
response, clinical remission, and corticosteroid-
free remission, at week 6 and/or 52 were
determined post hoc in patients aged\35, 35
to\55, and C55 years.
Results: At baseline, 353, 412, and 130
ulcerative colitis (UC) and 582, 443, and 90
Crohn’s disease (CD) patients were aged\35, 35
to\55, and C55. Of these patients, 56 were aged
C65 years (UC: 33, CD: 23). Trends favoring
vedolizumab over placebo were observed for
most efficacy endpoints irrespective of patient
age; some variability between subgroups was
observed. Safety profiles of vedolizumab and
placebo were similar in all age groups.
Vedolizumab-treated patients aged C55 had
the lowest incidence of serious infections (0.9
per 100 person–years) and adverse events
leading to hospitalization (14.8 per
100 person–years). There were no age-related
differences in the incidence of adverse
hematological events, malignancy, or death.
Conclusions: The safety and efficacy of
vedolizumab in patients with UC or CD were
similar for all age groups. The number of
patients in the oldest age group in these
analyses was small; thus further studies of
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INTRODUCTION
Inflammatory bowel disease (IBD) is a disorder of
the gastrointestinal tract that includes ulcerative
colitis (UC) and Crohn’s disease (CD) [1, 2]. The
prevalence of IBD in elderly patients is high, with
10–30% of the global IBD population over the
age of 60 [3]. The epidemiology, clinical
characteristics, and natural history of IBD are
heterogeneous with respect to age of onset, and
thus treatment should be individualized,
including considerations for age [4]. However,
safe and effective therapeutic options for aging
IBD patients are limited and treatment is
challenging, confounded by age-related
comorbidities, immunodeficiency, and overall
elevated rates of polypharmacy [5, 6].
Consequently, the incidence of treatment-
related adverse events and overall rates of
mortality and morbidity are higher in older IBD
patients [7, 8].
The therapeutic management of IBD in aging
populations is an active area of research, and
numerous studies have demonstrated marked
deficiencies and risks associated with the use of
several IBD treatments [6, 8–14]. For example,
anti-tumor necrosis factor (anti-TNF) therapies,
corticosteroids, and thiopurines—as individual
treatment regimens or in combination—are
associated with higher risks of malignancy and
opportunistic infections in elderly IBD patients
than their younger counterparts [8, 9, 11,
15–17]. Increased infection rates with anti-TNF
therapy in elderly IBD patients have, in turn,
been proposed as an underlying reason for high
rates of IBD treatment discontinuation [10] and
increased risk of mortality related to
hospitalizations [8]. Further, long-term,
high-frequency, or elevated-dose use of
corticosteroids—common in the elderly
population—may exacerbate several
cardiometabolic and cognitive conditions
[14, 18]. Oral corticosteroid therapy in elderly
patients is also linked to diabetes mellitus
[6, 19], which confers a nearly twofold
increased risk of infections such as sepsis,
pneumonia, and urinary tract infections in
patients treated with immunosuppressants
[13]. Rates of non-melanoma skin cancer and
risk of lymphoma associated with thiopurine
use were found to increase with increasing age
[17] or with successive years of therapy [16],
making long-term use undesirable.
Vedolizumab is a novel humanized
immunoglobulin G1 monoclonal antibody to
a4b7 integrin that selectively inhibits
inflammation in the gastrointestinal tract
without inhibiting systemic immune responses
[20]. This gut-selective mechanism of action
may be particularly relevant to aging
populations because of their elevated risk of
systemic infections and malignancy [16, 21].
The safety and efficacy of vedolizumab for
moderately to severely active UC and CD were
demonstrated in the phase 3 GEMINI 1 and
GEMINI 2 studies, respectively [22, 23].
However, aside from an analysis of the role of
age as a risk factor for infection for
vedolizumab-treated patients with UC or CD
[24], limited data exist on the safety and efficacy
of vedolizumab in older populations in part
because few patients over the age of 65 years
enrolled in the GEMINI 1 and GEMINI 2
studies. In this paper we use available study
data to report post hoc analyses of the safety
and efficacy of vedolizumab in patients grouped
by age. In an effort to include meaningful
numbers of patients in each age stratum, we
divided the population as follows: aged\35, 35
to \55, and C55 years. Recognizing that the
elderly population typically refers to those aged
C65 years, we provide safety and efficacy data
for GEMINI patients in this age group as well.
METHODS
These results are based on post hoc subgroup
analyses of data from the GEMINI 1 and
GEMINI 2 studies (ClinicalTrials.gov
Adv Ther (2017) 34:542–559 543
identifiers: NCT00783718 and NCT00783692,
respectively) which enrolled patients aged
18–80 years with moderately to severely active
UC or CD, respectively [22, 23]. We
retrospectively investigated the safety and
efficacy of vedolizumab in patients stratified
into the following age groups:\35, 35 to\55,
and C55 years. These data are also reported for
the age groups\65 and C65.
Study Designs
The GEMINI 1 and GEMINI 2 study designs
have been previously published [22, 23].
Patients received double-blind vedolizumab or
placebo [cohort 1; induction intent-to-treat
(ITT) population] or open-label vedolizumab
(cohort 2) during the induction phase
(Supplementary Fig. S1). Patients from either
cohort who demonstrated clinical response to
vedolizumab at week 6 received vedolizumab
every 8 weeks or every 4 weeks or placebo up to
week 52 beginning at week 6 (maintenance ITT
population) (Supplementary Fig. S1). Patients
who did not have clinical response at week 6
with vedolizumab induction therapy and
patients who had received placebo could
continue with vedolizumab every 4 weeks or
placebo, respectively, for the remainder of the
study (Supplementary Fig. S1). Patients
receiving stable doses of corticosteroids at
study baseline were permitted to continue
treatment, but had to begin a defined steroid
tapering regimen once response to vedolizumab
was achieved. At centers outside the USA,
patients were permitted to continue
stable doses of immunosuppressants
throughout the study. However, in the USA,
patients were required to discontinue
immunosuppressant use after the induction
phase. Patients who completed or withdrew
early from GEMINI 1 or GEMINI 2 during the
maintenance phase were eligible to enroll in the
open-label extension trial, GEMINI Long-term
Safety (LTS; ClinicalTrials.gov identifier:
NCT00790933). All patients received
open-label vedolizumab every 4 weeks during
GEMINI LTS.
Efficacy Analyses
The primary and secondary efficacy endpoints
from the GEMINI 1 and GEMINI 2 studies were
evaluated post hoc in patients according to
their age at baseline and compared
descriptively.
The primary endpoint for the GEMINI 1
induction phase was clinical response
[reduction in the complete Mayo Clinic score
of C3 points and C30% from baseline (week 0)
with an accompanying decrease in rectal
bleeding subscore of C1 point or absolute
rectal bleeding subscore of B1 point] at week
6. Secondary endpoints were clinical remission
(complete Mayo Clinic score of B2 and no
subscore of [1) and mucosal healing (Mayo
Clinic endoscopic subscore of 0 or 1) at week 6.
The primary endpoint for the GEMINI 1
maintenance phase was clinical remission at
week 52. Secondary endpoints at week 52 were
durable clinical response (clinical response at
both weeks 6 and 52), durable clinical remission
(clinical remission at both weeks 6 and 52),
mucosal healing, and corticosteroid-free
remission (clinical remission without
corticosteroid therapy in patients receiving
corticosteroids at baseline) [23].
The primary endpoints for the GEMINI 2
induction phase were clinical remission (CD
Activity Index (CDAI) score of B150 points) and
enhanced clinical response (C100-point
decrease in the CDAI score from baseline) at
week 6. The secondary endpoint at week 6 was
the mean change in C-reactive protein (CRP)
levels from baseline. The primary endpoint for
the GEMINI 2 maintenance phase was clinical
remission at week 52, and the secondary
endpoints at week 52 were enhanced clinical
response, corticosteroid-free remission (clinical
remission without corticosteroid therapy in
patients receiving corticosteroids at baseline),
and durable clinical remission (clinical
remission at C80% of study visits, including
the final visit) [22].
For each binary endpoint, the absolute
differences in percentages of patients meeting
the endpoint with vedolizumab and placebo
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were calculated, along with 95% confidence
intervals (CIs). For the continuous efficacy
endpoint (i.e., CRP levels), the mean change
from baseline was calculated for each treatment
group using the last observation carried forward
method and reported with its standard
deviation. For the week 52 efficacy endpoints,
the maintenance ITT vedolizumab every 8 week
and every 4 week groups were combined in each
study to increase the patient population of each
subgroup.
Safety Analyses
Safety data were collected from week 0 through
week 52 for all patients who received
vedolizumab at any time during the study and
all patients who received placebo only, and data
from both studies were pooled. Adverse events
were classified according to the Medical
Dictionary for Regulatory Activities (MedDRA),
version 14.0 [25]. Patients were monitored for
infusion-related reactions during and after the
infusion and were also instructed to alert
investigators of the development of such
reactions, including rash, hives, and pruritus.
Adverse events that were considered to be
infusion-related by the investigator were
recorded. In addition, malignancies, deaths,
and treatment-emergent adverse events
leading to hospitalizations were reported. Of
note, all safety results were based on a post hoc
subgroup analysis of data from the GEMINI 1
and GEMINI 2 studies, neither of which was
powered for safety analyses. Therefore,
descriptive statistics were used to compare
incidences of adverse events between the
different groups and no statistical conclusions
were made. Adverse events were presented as
the number of patients with the event and as
exposure-adjusted incidence rates, defined as
the number of patients experiencing the event
per 100 person–years (PY) of exposure. Exposure
was calculated separately for each adverse event
as the date of onset minus the date of first dose
plus 1. PY of exposure were calculated for the
first occurrence of each adverse event, and
truncated after a patient experienced the
adverse event. However, the patient could
continue to contribute PY for different adverse
events. Thus, the total PY of exposure for each
adverse event could differ.
Ethical Considerations
The study protocol and the informed consent
documentation were reviewed and approved by
the institutional review board(s) or independent
ethics committee(s) at each investigational
center. The study was conducted in
compliance with the protocol, good clinical
practice, and the applicable regulatory
requirements (including International
Conference on Harmonisation guidelines), and
in accordance with ethical principles founded
in the Declaration of Helsinki of 1964, as revised
in 2013. Written informed consent for being
included in the study was obtained from all




The majority of patients enrolled in either
GEMINI 1 or GEMINI 2 were\55 years of age
(Fig. 1 and Supplementary Fig. S1). GEMINI 1
enrolled 895 patients with moderately to
severely active UC, of whom 39%, 46%, and
15% were aged\35, 35 to\55, and C55 years,
respectively (Fig. 1a). GEMINI 2 enrolled 1115
patients with moderately to severely active CD,
of whom 52%, 40%, and 8% were \35, 35 to
\55, and C55 years of age (Fig. 1b). In GEMINI
1 and GEMINI 2 studies, 33 (4%) and 23 (2%)
patients, respectively, were aged C65 years.
There were no striking differences in the
distribution of ages between the treatment
groups in either study.
Differences between age groups were not
evaluated statistically and are characterized
descriptively in Tables 1 and 2. Overall,
baseline characteristics of the induction safety
populations—in particular concomitant
medications—were similar across the age
groups, except for disease duration (Tables 1
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and 2). In addition, disease location varied and
disease activity scores were lower for CD
patients C55 years old (Table 2). The mean
disease duration in UC patients aged\35 years
was\5 years, whereas the mean in patients aged
35 to\55 years and those aged C55 years was 8
and C9 years, respectively (Table 1). Mayo
Clinic scores were consistent across the age
groups (Table 1). The mean duration of CD
ranged from\7 years in patients\35 years old
to[12 years in patients C55 years old (Table 2).
Similarly, mean CDAI scores ranged from C325
in CD patients\35 years old to\310 in those
C55 (Table 2). In addition, a greater percentage
of CD patients aged\35 years had CD located in
both the ileum and the colon than those aged
C35 years (Table 2). After re-randomization of
vedolizumab responders at week 6, baseline
Fig. 1 Age of the patient population in GEMINI 1 and
GEMINI 2. Number of patients at each age at baseline in
a GEMINI 1 and b GEMINI 2 according to induction
treatment received. CD Crohn’s disease, ITT intent-to-
treat, OL open-label, PBO placebo, UC ulcerative colitis,
VDZ vedolizumab
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disease characteristics for the maintenance ITT
population were generally consistent with those
observed for the induction ITT population, with
no important differences between treatment
groups.
Approximately 40% of patients in each age
group completed the GEMINI 1 study. Of the
patients who enrolled in the GEMINI LTS study,
79 (30%), 141 (45%), and 42 (42%) UC patients
aged \35, 35 to \55, and C55 years,
Table 1 UC induction population demographics and baseline disease characteristics













Age (years), mean ± SD 28.1 ± 4.7 27.3 ± 4.6 45.0 ± 5.5 44.3 ± 5.9 63.3 ± 6.0 61.9 ± 5.8
Sex (male), n (%) 34 (64) 179 (60) 49 (63) 187 (56) 9 (50) 67 (60)
Duration of disease (years),
mean ± SD
4.3 ± 3.5 4.6 ± 3.6 8.0 ± 7.1 8.0 ± 6.2 11.5 ± 11.9 9.3 ± 9.1
Mayo Clinic score, mean ± SD 9.0 ± 1.7 8.6 ± 1.7 8.4 ± 1.7 8.6 ± 1.8 8.1 ± 1.6 8.3 ± 1.6
Partial Mayo Clinic score, mean ± SD 6.4 ± 1.5 6.1 ± 1.6 6.0 ± 1.5 6.0 ± 1.7 5.6 ± 1.5 5.7 ± 1.5
IBDQ score, mean ± SD 124 ± 33 120 ± 33 128 ± 34 122 ± 32 119 ± 36 125 ± 33
Disease site
Rectum and sigmoid colon only,
n (%)
5 (9) 40 (13) 13 (17) 42 (13) 4 (22) 12 (11)
Left side of colon, n (%) 19 (36) 91 (30) 35 (45) 135 (40) 5 (28) 54 (48)
Proximal to the splenic ﬂexure, n (%) 12 (23) 43 (14) 5 (6) 35 (10) 1 (6) 13 (12)
All of the colon, n (%) 17 (32) 126 (42) 25 (32) 122 (37) 8 (44) 33 (29)
Concomitant medication for UC
CS only, n (%) 21 (40) 105 (35) 30 (38) 128 (38) 7 (39) 41 (37)
IS only, n (%) 5 (9) 64 (21) 12 (15) 56 (17) 1 (6) 21 (19)
CS and IS, n (%) 10 (19) 50 (17) 13 (17) 54 (16) 3 (17) 19 (17)
No CS or IS, n (%) 17 (32) 81 (27) 23 (29) 96 (29) 7 (39) 31 (28)














Prior anti-TNF therapy, n (%)b 25 (47) 146 (49) 38 (49) 161 (48) 10 (56) 51 (46)
Prior anti-TNF failure, n (%)a 21 (40) 121 (40) 32 (41) 140 (42) 10 (56) 43 (38)
CS corticosteroid, IBDQ inﬂammatory bowel disease questionnaire, IS immunosuppressant, PBO placebo, SD standard
deviation, TNF tumor necrosis factor alpha, UC ulcerative colitis, VDZ vedolizumab
a Includes patients from cohort 1 and cohort 2
b Prior anti-TNF exposure was recorded on the interactive voice response system during screening and enrollment. Prior
anti-TNF failure was recorded on the case report form at study baseline (week 0). Because of the different data sources, the
number of patients with prior anti-TNF exposure does not equal those with prior anti-TNF failure
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respectively, were still continuing open-label
vedolizumab treatment at 100 weeks
post-enrollment (Supplementary Fig. S1a), and
24 (9%), 27 (9%), and 9 (9%), respectively,
discontinued GEMINI LTS because of an adverse
event. In GEMINI 2 study, 48% of the
C55-year-old patient population completed
the study versus 36% and 38% of the
\35-year-old and 35- to \55-year-old patient
populations, respectively. Of the CD patients
who enrolled in the GEMINI LTS study, 127
(35%) patients \35 years old were still
continuing treatment at 100 weeks
post-enrollment, and 150 (51%) and 33 (51%)
were continuing at this same time point in the
35- to \55- and the C55-year-old age groups,
Table 2 CD induction population demographics and baseline disease characteristics













Age (years), mean ± SD 27.1 ± 4.0 26.5 ± 4.4 43.5 ± 5.4 43.4 ± 5.7 64.1 ± 6.0 61.4 ± 5.3
Sex (male), n (%) 31 (46) 261 (51) 31 (49) 159 (42) 7 (39) 31 (43)
Duration of disease (years),
mean ± SD
6.1 ± 4.4 6.6 ± 4.9 9.4 ± 7.8 11.5 ± 8.4 12.1 ± 13.9 14.9 ± 12.5
CDAI score, mean ± SD 336 ± 89 325 ± 70 318 ± 67 324 ± 65 307 ± 66 308 ± 63
IBDQ score, mean ± SD 113 ± 26 121 ± 30 117 ± 34 118 ± 31 112 ± 36 122 ± 33
Disease site
Ileum only, n (%) 6 (9) 66 (13) 11 (17) 73 (19) 4 (22) 21 (29)
Colon only, n (%) 17 (25) 136 (26) 19 (30) 111 (29) 7 (39) 26 (36)
Ileum and colon, n (%) 44 (66) 313 (61) 33 (52) 196 (52) 7 (39) 25 (35)
Concomitant medication for CD
CS only, n (%) 18 (27) 176 (34) 18 (29) 134 (35) 9 (50) 26 (36)
IS only, n (%) 17 (25) 82 (16) 7 (11) 63 (17) 1 (6) 11 (15)
CS and IS, n (%) 14 (21) 98 (19) 11 (17) 61 (16) 1 (6) 4 (6)
No CS or IS, n (%) 18 (27) 159 (31) 27 (43) 122 (32) 7 (39) 31 (43)














Prior anti-TNF therapy, n (%)b 34 (51) 321 (62) 30 (48) 249 (66) 8 (44) 47 (65)
Prior anti-TNF failure, n (%)a 35 (52) 300 (58) 29 (46) 231 (61) 6 (33) 44 (61)
Prior surgery for CD, n (%) 24 (36) 190 (37) 23 (37) 181 (48) 7 (39) 41 (57)
CD Crohn’s disease, CDAI Crohn’s disease activity index, CS corticosteroid, IBDQ inﬂammatory bowel disease
questionnaire, IS immunosuppressant, PBO placebo, SD standard deviation, TNF tumor necrosis factor alpha, VDZ
vedolizumab
a Includes patients from cohort 1 and cohort 2
b Prior anti-TNF exposure was recorded on the interactive voice response system during screening and enrollment. Prior
anti-TNF failure was recorded on the case report form at study baseline (week 0). Because of the different data sources, the
number of patients with prior anti-TNF exposure does not equal those with prior anti-TNF failure
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respectively (Supplementary Fig. S1b). Forty-five
(12%), 36 (12%), and 5 (8%) patients aged\35,
35 to \55, and C55 years, respectively,
discontinued GEMINI LTS because of an
adverse event.
Clinical Efficacy in UC
Vedolizumab induction treatment consistently
resulted in numerically greater percentages of
UC patients meeting each endpoint at week 6
than placebo (Fig. 2a and Supplementary
Fig. S2). At 6 weeks, 44 (51%), 50 (47%), and
12 (38%) vedolizumab-treated patients aged
\35, 35 to \55, and C55 years, respectively,
achieved clinical response (Fig. 2a). Further, no
differences in treatment benefit were observed
between age groups among patients achieving
clinical remission or mucosal healing at
6 weeks, with those aged C55 years exhibiting
the largest 95% CIs (Supplementary Fig. S2). Of
the eight vedolizumab-treated patients aged
C65 years in the induction ITT group, three
achieved a clinical response at week 6
(Supplementary Table S1).
Among vedolizumab-treated patients with
response at week 6 who entered the GEMINI 1
maintenance phase, 34 (34%), 58 (53%), and 15
(42%) who achieved clinical remission at week
52 with continued vedolizumab treatment
Fig. 2 Induction and maintenance phase primary
endpoints in UC patients by baseline age group.
a Clinical response at week 6 in the induction ITT
population and b clinical remission at week 52 in the
maintenance ITT population. CI conﬁdence interval, ITT
intent-to-treat, PBO placebo, UC ulcerative colitis, VDZ
vedolizumab. aPatients received VDZ during induction
and PBO during maintenance. bPatients received VDZ
during induction and VDZ every 4 weeks or every 8 weeks
during maintenance
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(Fig. 2b). Generally, similar percentages of
vedolizumab-treated patients from each age
group achieved durable clinical response,
durable clinical remission, mucosal healing,
and corticosteroid-free remission at week 52,
with no noticeable age-related trends
(Supplementary Fig. S3). At week 52, clinical
remission was achieved in 3 of the 11 patients
aged C65 years who received vedolizumab every
8 or every 4 weeks during the maintenance
phase (Supplementary Table S1).
Clinical Efficacy in CD
An overall trend favoring vedolizumab
treatment was observed in the induction and
maintenance phases of the GEMINI 2 study. At
week 6, percentages of vedolizumab-treated
patients who achieved clinical remission in the
\35-year-old (14%) and the 35- to\55-year-old
(16%) age groups were similar and higher than
in the C55-year-old age group (8%) (Fig. 3a).
The percentage of vedolizumab-treated patients
with enhanced clinical response increased with
increasing age group (28%, 33%, and 46%,
respectively) (Fig. 3b). Of the two
vedolizumab-treated patients C65 years old in
the induction ITT group, one achieved
enhanced clinical response and clinical
remission at week 6 (Supplementary Table S2).
At 6 weeks, the mean change from baseline
serum CRP levels did not differ with
vedolizumab treatment across the age groups
(Supplementary Table S3).
After re-randomization of patients with
clinical response at week 6, similar percentages
of vedolizumab-treated patients in all age
subgroups achieved clinical remission (Fig. 3c),
enhanced clinical response (Supplementary
Fig. S4), and corticosteroid-free remission
(Supplementary Fig. S4) at week 52.
Vedolizumab maintenance treatment resulted
in 20%, 19%, and 9% of patients aged\35, 35 to
\55, and C55 years, respectively, achieving
durable clinical remission (Supplementary
Fig. S4). Two of the five patients C65 years old
achieved clinical remission in the group that
received vedolizumab every 8 or every 4 weeks
(Supplementary Table S2).
Safety in UC and CD
The safety profile of vedolizumab in the total
combined GEMINI 1 and GEMINI 2 population
was similar across all age groups investigated.
The most common adverse events reported
were nasopharyngitis, headache, arthralgia,
and nausea, each occurring with an incidence
of C10 patients per 100 PY in the combined
vedolizumab-exposed patient population in
each age group (Table 3). Of these, in patients
C55 years old, the incidence of nasopharyngitis,
nausea, and upper respiratory tract infection, as
well as pyrexia, appeared higher in
vedolizumab-treated patients than in the
placebo group (Table 3). Patients C65 years old
reported a generally similar adverse event
profile to patients \65 years old
(Supplementary Table S4).
The rates of adverse events were generally
similar across all age groups. Rates of any
adverse events per 100 PY were 337.8, 364.6,
and 343.8 in vedolizumab-treated patients aged
\35, 35 to \55, and C55 years, respectively,
versus 482.6, 323.6, and 394.3 in patients who
received placebo (Table 3). Infusion-related
reactions were uncommon and occurred at
similar rates throughout the age and treatment
groups (Table 3). Psoriasis—an adverse event
observed with anti-TNF therapy [26]—in
particular, was reported in \2 patients per
100 PY in any treatment group, irrespective of
patient age. Memory impairment, when
captured as an adverse event verbatim, was
reported for 7 (1.4 per 100 PY), 8 (1.8 per
100 PY), and 4 (3.6 per 100 PY)
vedolizumab-treated patients aged \35, 35 to
\55, and C55 years, respectively, versus 0, 1
(1.2 per 100 PY), and 1 (4.3 per 100 PY) patients
who received placebo.
In general, rates of infections were similar
across all age groups (Table 3). No patient
C55 years of age in either the vedolizumab- or
placebo-exposed group had a clostridia
infection versus \0.7 per 100 PY in any
combined vedolizumab-treated population
aged\35 or 35 to\55 years. The incidence of
pneumonia was B1.4 per 100 PY in
vedolizumab-treated patients in any age group.
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There were no reports of progressive multifocal
leukoencephalopathy.
No increase in the occurrence of diabetes was
apparent with age or with vedolizumab
compared with placebo. Type 2 diabetes
mellitus was reported with vedolizumab
treatment in one patient\35 years old (0.2 per
100 PY) and one patient C55 years old (0.9 per
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100 PY). Blood glucose increased in \0.7
patients per 100 PY in all vedolizumab-
exposed age groups and \1.2 in all
placebo-exposed age groups analyzed. In
addition, no meaningful differences were
observed in the percentage of patients with
adverse hematological events, in general,
between vedolizumab and placebo treatment
in any age group (Supplementary Table S5).
Similarly, the occurrence of serious adverse
events, including serious infections, was
generally consistent across all age groups
(Table 3). However, the incidence of serious
adverse events in vedolizumab-treated patients
was lowest in patients aged C55 years, with
serious events reported in 17 patients aged
C55 years (15.9 per 100 PY) versus 149 (32.1
per PY) and 110 (27.5 per PY) patients aged\35
and 35 to \55 years, respectively (Table 3).
Compared with younger vedolizumab-treated
patients, those receiving vedolizumab in the
C55-year-old age group had the lowest
incidence of adverse events leading to
hospitalizations (Table 3). The most common
adverse events that led to hospitalization in
vedolizumab-treated patients aged \35, 35 to
\55, and C55 years were exacerbation of UC
(3%, 4%, and 1% of patients, respectively) and
CD (10%, 4%, and 3% of patients, respectively).
No other individual adverse event led to
hospitalization in[2% of vedolizumab-treated
patients in any age group.
Malignancies were reported in two
vedolizumab-treated patients aged \35 years
(0.4 per 100 PY), two vedolizumab-treated
patients aged 35 to\55 years (0.5 per 100 PY),
and one patient who received placebo aged
C55 years (4.3 per 100 PY) (Table 3). There were
two additional malignancies reported in the
maintenance ITT placebo population (Table 4),
a group not represented in the safety population
in Table 3. Overall, there was no apparent
relationship to age in the number or type of
malignancy reported. All patients with
malignancy had risk factors that may have
contributed to the etiology, including prior
therapy with immunosuppressives, smoking
history, and/or history of a prior cancer or
related medical condition. Of the two patients
aged C55 years, one had received only placebo
before being diagnosed with squamous
cell carcinoma of the nose, which was
resolved following excision. The second
patient, a 73-year-old male with colon cancer,
had a 14-year history of UC limited to
the rectum and sigmoid colon. Both patients
had previously received azathioprine/
mercaptopurine and corticosteroids (rectal and
systemic).
Six deaths occurred during the studies: three
vedolizumab-treated CD patients aged
\35 years, one vedolizumab-treated CD
patient aged 46 years, and two patients
C55 years old, one of whom, a 75-year-old CD
patient, had received only placebo
(Supplementary Table S6). A 66-year-old male
UC patient died of reported acute cardiac death
14 days after his first induction dose of
open-label vedolizumab. His medical record
included a 2-year history of chronic ischemic
heart disease, and the postmortem examination
showed diffuse multifocal cardiosclerosis.
Detailed accounts of all deaths have been
described previously [22, 23].
DISCUSSION
The post hoc analyses we report descriptively
show that the efficacy of vedolizumab
induction and maintenance therapy for UC
and CD is generally similar between patients
aged \35, 35 to \55, and C55 years, and no
age-related differences were observed in the
adverse event profile. As would be expected,
disease duration was longer in the older
GEMINI patients; however, an increase in
bFig. 3 Induction and maintenance phase primary
endpoints in CD patients by baseline age group.
a Clinical remission at week 6 in the induction ITT
population, b enhanced clinical response at week 6 in the
induction ITT population, and c clinical remission at week
52 in the maintenance ITT population. CD Crohn’s
disease, CI conﬁdence interval, ITT intent-to-treat, PBO
placebo, VDZ vedolizumab. aPatients received VDZ during
induction and PBO during maintenance. bPatients
received VDZ during induction and VDZ every 4 weeks
or every 8 weeks during maintenance
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disease severity was not observed with longer
disease duration, as evidenced by baseline
disease activity scores. Thus, the consistent
efficacy and safety observed with increasing
age were not confounded by variations in
disease severity. These data are promising and
especially relevant because of the rapidly rising
global population of patients over the age of 60
[27]. However, both studies enrolled small
numbers of patients C65 years of age and
therefore further studies of the safety and
efficacy of vedolizumab in the elderly
population are needed.
There are currently no formal guidelines for
the treatment of IBD in elderly populations,
leaving substantial gaps in the treatment
paradigm [5]. Elderly patients are
underrepresented in clinical trials, and the
sparse data that are available for this
population indicate that managing elderly
patients with IBD is complex and disparate
from IBD management in younger patients.
Factors that contribute to the complexity
include the potential for a smaller response to
treatment, altered clinical course of IBD, and
increased risk of malignancies and infections [5].
Clinical trials often exclude the elderly
population either explicitly or implicitly
through exclusion criteria and intensity of
study-related visits. As a result, older patients
are not well represented in phase 3 clinical trials
[3]. Indeed, the median patient age in most IBD
studies is generally around the thirties [3].
Similarly, neither GEMINI 1 nor GEMINI 2 was
designed to investigate these subgroups
specifically. Thus, these post hoc analyses are
limited by small sample size and are not
adequately powered to detect statistically
significant differences. However, the efficacy of
vedolizumab in UC and CD patients relative to
placebo was overall consistent across all
endpoints, irrespective of the patient’s age
group. Further, experience with anti-TNF
therapy has shown an inverse relationship
between disease duration and clinical efficacy
[28], suggesting that efficacy may decline as
patients age. In the vedolizumab GEMINI 1 and
GEMINI 2 studies, patients aged C55 years had
longer disease duration than their younger
counterparts but experienced similar clinical
benefits, although some variability between
subgroups was observed. For example, no
Table 4 Malignancies reported in patients with UC and CD
Age No. of
events




\35 years 2 20.7/F CD Carcinoid tumor of
the appendix
VDZ/VDZ (Q4 W) 14
32.7/M UC Colon cancer VDZ/VDZ (Q8 W) 7
35 to
\55 years
3 40.5/M UC Transitional cell
carcinoma
VDZ/PBO 2a
45.2/F CD Breast cancer Cohort 2 VDZ (induction
only)
2
52.1/F CD Squamous cell
carcinoma (skin)
VDZ/VDZ (Q4 W) 11
C55 years 2 70.7/F UC Squamous cell
carcinoma
PBO/PBO 0
73.7/M UC Colon cancer VDZ/PBO 2a
CD Crohn’s disease, ITT intent-to-treat, PBO placebo, Q4 W every 4 weeks, Q8 W every 8 weeks, UC ulcerative colitis,
VDZ vedolizumab
a Received 2 doses of VDZ during induction
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difference was observed between vedolizumab
and placebo treatment in the percentages of CD
patients with corticosteroid-free remission at
week 52 among those aged C55 years. However,
this observation in CD could be attributed to
the small patient population with corticosteroid
use at baseline in this age group (seven patients
in each treatment group). Indeed, wide 95% CIs
were associated with the percentage-point
differences from placebo in the majority of
endpoints for patients aged C55 years, reflecting
variability in the data likely due to the small
number of patients in these post hoc subgroup
analyses. Corticosteroid sparing is particularly
important for older IBD patients since
long-term, high-frequency or high-dose
corticosteroid use in these patients often
exacerbates conditions such as congestive
heart failure, diabetes, hypertension,
osteoporosis, psychosis, depression, electrolyte
abnormalities, cataracts, glaucoma, or
infections [14, 18]. Yet chronic corticosteroid
use coupled with infrequent attempts to taper is
a common practice in elderly IBD patients aged
C65 years [14, 29]. Importantly, the absolute
percentages of patients achieving
corticosteroid-free remission with vedolizumab
maintenance treatment at week 52 were similar
for all UC patients (33–42%) and CD patients
(27–33%) regardless of age.
A recent integrated study of the vedolizumab
clinical trials, including GEMINI 1 and GEMINI
2, found younger age was a risk factor for serious
infection with vedolizumab exposure in a
combined population of 2884 patients with
UC or CD (hazard ratio 0.98; 95% CI 0.97–0.99;
P\0.001) but did not report any other
safety–age relationships [24]. Indeed, we
observed 10 fewer patients with infection per
100 PY of vedolizumab in the C55-year-old age
group than in the \35-year-old age group.
Further, we found no evidence of a change in
occurrence of malignancy, diabetes, other
adverse hematological events, or
infusion-related reactions with vedolizumab
treatment in patients with advancing age from
\35 to C55 years. No major age-related trends
in the occurrence of the most common adverse
events reported were observed. While cognitive
function was not evaluated directly in GEMINI
1 and GEMINI 2, the occurrence of an adverse
event of memory impairment with
vedolizumab was low [4 patients (3%; 3.6 per
100 PY) aged C55 years] and similar to that
observed with placebo [1 patient (3%; 4.3 per
100 PY) aged C55 years] in all age groups
investigated. One malignancy was reported in
a patient C55 years of age exposed to
vedolizumab induction; however, patient risk
factors (i.e., a history of tobacco use, a long
duration of UC, and prior therapy with
immunosuppressives and corticosteroids) may
have contributed to the etiology. Recently, a
retrospective study of 14,733 patients with
moderately to severely active IBD reported an
incidence of 0.7 per 100 PY for primary solid
tumors [30]. In comparison, the incidence of
cancer was B0.5 per 100 PY in our combined
vedolizumab-exposed population. Notably, a
1-year controlled study may not be long
enough to detect malignancies and other
adverse events that usually take longer to
develop. Continued monitoring through
epidemiological studies and patient registries
will help evaluate the long-term safety profile of
vedolizumab. Of note, percentages of UC and
CD patients C55 years of age who completed
the 52-week GEMINI 1 and GEMINI 2 studies
and of those who were continuing in the
open-label GEMINI LTS trial at 100 weeks
post-enrollment were similar to those of
patients\55 years of age. In contrast, anti-TNF
therapies have been linked to premature
discontinuation in older IBD patients more
often than younger patients [10, 31]. In one
retrospective single-center study, 53% of
patients aged [60 years were continuing
anti-TNF therapy at 12 months after initiation
versus 90% of younger users [10]. The increased
susceptibility of older patients to infectious
complications and adverse events, in general,
has been proposed as an underlying reason for
premature treatment cessation in this
population [10, 31].
Overall, the current analysis highlighted
important trends in the data favoring
vedolizumab over placebo for most efficacy
endpoints irrespective of age. Safety profiles
were found to be similar between vedolizumab
and placebo in all age groups. However, given
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the limitations of this study, further
investigation of the safety and efficacy of
vedolizumab in the elderly population is
needed. As mentioned earlier, the current
results are based on a post hoc subgroup
analysis of data from the GEMINI 1 and
GEMINI 2 studies, both of which were limited
in size (particularly for patients C65 years of
age) and duration; and therefore they were not
powered for efficacy or safety analyses [22, 23].
Further, as a result of the multiplicity of adverse
events and the spontaneous nature of adverse
event reporting, descriptive statistics were used
to compare the incidences of adverse events
between patient groups in the original pivotal
studies and the current subgroup analyses.
Finally, comorbidities, especially as patients
age, may confound study results; however,
monitoring of comorbidities was not
prespecified in the trial designs, making
stratification of patients based on comorbid
conditions challenging.
CONCLUSIONS
Because of changing demographics, the safe and
effective treatment of older IBD patients will be
an ongoing challenge. The results of these post
hoc analyses suggest that vedolizumab treatment
was efficacious and well tolerated in IBD patients
across all ages. Based on these results, and within
the limitation of these analyses, vedolizumab
may offer an attractive alternative to the
currently available treatment options. In the
absence of prospective interventional studies
investigating the effects of vedolizumab in
elderly patients, the emergence of real-world
data will add to the findings of these post hoc
analyses and provide further support for whether
vedolizumab is a suitable treatment option for
elderly IBD patients.
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